This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Michael Meyers Biography and Net Worth

SVP of Syndax Pharmaceuticals

Michael L. Meyers, M.D., Ph.D. has served as our Senior Vice President, Chief Medical Officer since May 2016. Dr. Meyers previously served as our Senior Vice President, Chief Development Officer from August 2015 to April 2016. Prior to joining us, Dr. Meyers held a number of senior roles at Johnson & Johnson, a publicly traded pharmaceutical, medical device, and consumer packaged goods company, serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Dr. Meyers also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc., a privately held life sciences company, predecessor to Sanofi-Aventis U.S. LLC, and worked in oncology clinical development at the Schering-Plough Research Institute. Dr. Meyers served on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma. He received his M.D. and his Ph.D. in Microbiology and Immunology from Albert Einstein College of Medicine in New York and was elected to the Alpha Omega Alpha, the national medical school honor society. Dr. Meyers completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center.

What is Michael L. Meyers' net worth?: The estimated net worth of Michael L. Meyers is at least $322,249.62 as of April 26th, 2021. Dr. Meyers owns 15,666 shares of Syndax Pharmaceuticals stock worth more than $322,250 as of April 25th. This net worth approximation does not reflect any other assets that Dr. Meyers may own. Learn More about Michael L. Meyers' net worth.
How do I contact Michael L. Meyers?: The corporate mailing address for Dr. Meyers and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Michael L. Meyers' contact information.
Has Michael L. Meyers been buying or selling shares of Syndax Pharmaceuticals?: Michael L. Meyers has not been actively trading shares of Syndax Pharmaceuticals over the course of the past ninety days. Most recently, on Monday, April 26th, Michael L. Meyers bought 500 shares of Syndax Pharmaceuticals stock. The stock was acquired at an average cost of $15.46 per share, with a total value of $7,730.00. Following the completion of the transaction, the senior vice president now directly owns 15,666 shares of the company's stock, valued at $242,196.36. Learn More on Michael L. Meyers' trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Pierre Legault (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, insiders at the sold shares 6 times. They sold a total of 294,997 shares worth more than $6,006,050.17. The most recent insider tranaction occured on August, 9th when Director Briggs Morrison sold 52,855 shares worth more than $965,660.85. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 8/9/2023.

Michael L. Meyers Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/26/2021	Buy	500	$15.46	$7,730.00	15,666
3/21/2019	Buy	1,104	$4.92	$5,431.68

Michael L. Meyers Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $20.57

$20.13

$20.80

50 Day Range

MA: $22.69

$20.49

$24.57

2 Week Range

Now: $20.57

$11.22

$25.34

Volume

588,963 shs

Average Volume

1,133,732 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad